Clinical effectiveness of platelets in additive solution treated with two commercial pathogen-reduction technologies-Reference-Cited by-同舟云学术

Clinical effectiveness of platelets in additive solution treated with two commercial pathogen-reduction technologies

Published:2017-02-24 Issue:5 Volume:57 Page:1171-1183
ISSN:0041-1132
Container-title:Transfusion
language:en
Short-container-title:EDITORIAL

Author:

Rebulla Paolo¹,Vaglio Stefania²,Beccaria Francesco³,Bonfichi Maurizio⁴,Carella Angelo³,Chiurazzi Federico⁵,Coluzzi Serelina⁶,Cortelezzi Agostino⁷,Gandini Giorgio⁸,Girelli Gabriella⁶,Graf Maria⁵,Isernia Paola⁴,Marano Giuseppe²,Marconi Maurizio¹,Montemezzi Rachele⁸,Olivero Barbara¹,Rinaldi Marianna⁸,Salvaneschi Laura⁴,Scarpato Nicola⁵,Strada Paolo³,Milani Silvano⁹,Grazzini Giuliano²

Affiliation:

1. Blood Transfusion Service, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico; Milan Italy

2. Italian National Blood Center, National Institute of Health; Rome Italy

3. Blood Transfusion Service and Hematology 1; IRCCS San Martino University Hospital; Genoa Italy

4. Blood Transfusion Service and Hematology; IRCCS Policlinico San Matteo; Pavia Italy

5. Blood Transfusion Service and Hematology; Federico II University Hospital; Naples Italy

6. Blood Transfusion Service and Hematology; Umberto I Hospital; Rome Italy

7. Hematology, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico and University of Milan; Milan Italy

8. Blood Transfusion Service and Hematology; University Hospital; Verona Italy

9. Laboratory of Medical Statistics and Biometry, Department of Clinical Sciences and Community Health; University of Milan; Milan Italy

Funder

Italian Ministry of Health

Cerus Corp

Terumo BCT

Publisher

Wiley

Subject

Hematology,Immunology,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/trf.14042/fullpdf

Reference37 articles.

1. Component pathogen inactivation: a critical review;Prowse;Vox Sang,2013

2. Development of blood transfusion product pathogen reduction treatments: a review of methods, current applications and demands;Salunkhe;Transfus Apher Sci,2015

3. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial;Rhenen;Blood,2003

4. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT trial;McCullough;Blood,2004

5. Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial;Snyder;Transfusion,2005

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Platelet Pathogen Reduction Technology—Should We Stay or Should We Go…?;Journal of Clinical Medicine;2024-09-10

2. Results of clinical effectiveness of conventional versus Mirasol‐treated Apheresis Platelets in Patients with Hypoproliferative Thrombocytopenia (MiPLATE) trial;Transfusion;2024-02-05

3. Therapeutic efficacy and safety of pathogen‐reduced platelet components: Results of a meta‐analysis of randomized controlled trials;Vox Sanguinis;2024-01-05

4. Analysis of Transfusion-Transmitted Bacterial Infections according to German Hemovigilance Data (2011–2020);Transfusion Medicine and Hemotherapy;2022-12-29

5. THERAFLEX ultraviolet C (UVC)-based pathogen reduction technology for bacterial inactivation in blood components: advantages and limitations;Annals of Blood;2022-09